We carried out a retrospective chart review of all patients with chronic CSC involving the fovea treated with HF-PDT and followed-up at least for 6 months.


Recorded parameters included Best-Corrected Visual Acuity (BCVA) in logMAR, Central Subfield Thickness (CST) by Cirrus OCT and any adverse event occurred at baseline and during follow-up visits. 23 eyes of 23 patients were included.


Mean follow-up time (SD, MIN-MAX) was of 502 days (240, 180-1076). Between baseline and the end of follow-up BCVA increased from 0.5 to 0.2 (p<0.05, Wilcoxon test). Analogously CST decreased from 361 to 260 um (p=0.002, Wilcoxon test). In 2 eyes (8.7%) sub-retinal fluid increased after the first HF-PDT, but disappeared with the second treatment. All eyes showed a complete resolution of fluid at the end of their follow-up. 4 eyes (17.4%) had a deterioration of their final BCVA despite the restoration of the normal foveal contour. Mean number of treatment was 1.5: 5 eyes (21.7%) received 2 HF-PDT, 2 eyes (8.7%) 3 and 1 eye (4.3%) 4. No adverse events were recorded.


Half-fluence PDT to treat chronic CSC is a safe treatment that results in long-lasting both structural and functional improvements.

Contact Details:

Email: tassinaripaolo@tiscali.it
Cell Phone: +393495714704

Paolo Tassinari